Orbimed Advisors LLC Gracell Biotechnologies Inc. Transaction History

Orbimed Advisors LLC

  • $4.24 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$2.83 - $4.9 $778,250 - $1.35 Million
275,000 Added 3.04%
9,308,726 $26.8 Million
Q2 2023

Aug 14, 2023
SELL
$1.45 - $6.07 $672,869 - $2.82 Million
-464,048 Reduced 4.89%
9,033,726 $34.4 Million
Q1 2023

May 15, 2023
BUY
$1.8 - $2.5 $2.9 Million - $4.03 Million
1,612,904 Added 20.46%
9,497,774 $17.7 Million
Q1 2021

May 17, 2021
BUY
$14.7 - $30.57 $116 Million - $241 Million
7,884,870 New
7,884,870 $121 Million

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email